Bradley Merrill Thompson Comments on the MEDTECH Act – Media Coverage RoundupMultiple Publications December 5, 2014
Bradley Merrill Thompson, Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in multiple publications regarding the Medical Electronic Data Technology Enhancement for Consumers’ Health (MEDTECH) Act, a bill aimed at limiting FDA regulation of health IT software.
Following is an excerpt from Reuters:
"The act takes a straightforward and clean approach and as a result is less likely to have unintended consequences," added Bradley Merrill Thompson, an FDA-specialist with the Washington D.C.-based legal firm Epstein Becker & Green.
Merrill Thompson said the bill would retain FDA oversight over medium-risk or high-risk software, and technology that serves as an accessory to a medical device. But the bill does not propose any specific body or agency that would be charged with determining levels of risk.
Bloomberg BNA’s Medical Devices Law & Industry Report, 12/05/2014
The Gray Sheet, 12/05/2014
POLITICO Pro, 12/04/2014
FDA Week, 12/04/2014
FDA Week, 11/28/2014
Inside Health Policy's Inside CMS, 11/27/2014
American Health Line, 11/25/2014
Ortho Spine News, 11/25/2014
Health Data Management, 11/25/2014
mHealth News, 11/25/2014
Inside Health Policy’s New Congress Watch, 11/24/2014
POLITICO’s Morning eHealth, 11/24/2014
Modern Healthcare, 11/21/2014